The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

A compound represented by general formula (I)

##STR00001##

(wherein, all the symbols are as defined in the specification) has a selective S1P.sub.5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; .i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P.sub.5-mediated disease, e.g., neurodegenerative disease such as schizophrenia.

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

The presently disclosed subject matter relates to feed additive formulations for monogastric animal feed. Particularly, the disclosed formulations comprise an isolated xylanase enzyme and a B. licheniformis strain PWD-1. The feed additive formulations may further include B. amyloliquefaciens strain Ba-BPD1. The disclosed formulations are useful for addition to feeds for monogastric animals to synergistically improve the performance of the animals.

The presently disclosed subject matter relates to feed additive formulations for monogastric animal feed. Particularly, the disclosed formulations comprise an isolated xylanase enzyme and a B. licheniformis strain PWD-1. The feed additive formulations may further include B. amyloliquefaciens strain Ba-BPD1. The disclosed formulations are useful for addition to feeds for monogastric animals to synergistically improve the performance of the animals.

Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

The present invention relates to compositions comprising an inactivated Mycobacterium or an immunogenic fraction thereof, for use in the prevention of an infection in a subject, wherein the infection is selected from the group consisting of a protozoan parasitic infection and a bacterial infection, with the proviso that the infection is not caused by a Mycobacterium.

The present invention relates to compositions comprising an inactivated Mycobacterium or an immunogenic fraction thereof, for use in the prevention of an infection in a subject, wherein the infection is selected from the group consisting of a protozoan parasitic infection and a bacterial infection, with the proviso that the infection is not caused by a Mycobacterium.